Clinical Trials Logo

Clinical Trial Summary

Hypothesis

Nevirapine resistance developed in women and infants in the HIVNET 006 and 012 cohorts as a consequence of use of an agent with a long t½ as monotherapy in individuals with high viral loads.

Objective 1 To demonstrate that Nevirapine resistance does not develop in HIV infected patients when used as part of triple antiretroviral combination therapy between the initiation of treatment and suppression of HIV RNA to <1000 copies/ml.

Objective 2 To demonstrate that resistance to nevirapine does not develop when patients with suppressed HIV RNA discontinue combination antiretroviral therapy which contains nevirapine.


Clinical Trial Description

The HIVNET 012 clinical trial demonstrates a cost effective strategy to prevent maternal fetal transmission of HIV. In this study, a single 200 mg dose of Nevirapine was given to pregnant Ugandan women at the onset of labour and a single 2 mg/kg dose to their infants within 72 hours of birth (1). Given the efficacy, simplicity and low cost of this regime, the World Health Organization recently recommended implementation of this regimen as one of several options for prevention of maternal fetal transmission of HIV in resource limited settings.

Pharmacokinetic studies have demonstrated that 200 mg of Nevirapine given to the mother during labour results in concentrations >100 mg/mL (10 times the in vitro IC50) in the newborn. Nevirapine elimination is prolonged in both mothers and infants with median t½ of 36.8 to 65.7 hours. Administration of 200 mg orally to the mother and a single 2 mg/kg oral dose to the infant at 48-72 hours, maintains serum concentration in the infants >100 mg/ml through 7 days of life (2, 3)

Early studies demonstrated that the use of Nevirapine monotherapy resulted in a rapid selection of Nevirapine resistant mutations (4). This was associated with loss of antiviral activity and return of the viral load to baseline within 12 weeks. It appeared very soon that the non-nucleoside reverse transcriptase inhibitors were drugs with a low genetic barrier and that a single mutation in the reverse transcriptase gene induced a high level of phenotypic resistance (5). Similarly, when Nevirapine was used in combination with a single nucleoside, and there was incomplete suppression of viral replication, resistance emerged to the non-nucleoside reverse transcriptase inhibitor (6).

In contrast, when used as part of triple antiretroviral combination and there was successful inhibition of viral replication to <50 copies/ml, the viral response was maintained in 50% of patients out to 48 weeks (7, 8, 9, 10). However, again when virologic control is lost, resistance to Nevirapine emerges rapidly in 50-100% of patients (11). It is unclear whether or not these mutations developed during the initial suppression of viral load replication or during rebound of viremia with failure.

Given the pharmacokinetics of Nevirapine in pregnant women and infants, concern was raised that mother and child would be exposed to Nevirapine monotherapy for one to several days and that the selection of resistant mutants could arise limiting this strategy over the long term. In fact, a recent sub-analysis of the HIVNET 012 cohort found Nevirapine resistant mutations in 21/111 (19%) of women tested at 6-8 weeks after delivery. The K103N was the most common mutation. Women with the highest baseline viral load developed the mutations more frequently. Nevirapine resistant mutations were also detected in 11/24 or (46%) of infected infants at 6-8 weeks. In contrast to the mothers, the Y181C was the most commonly detected.

Similarly, the K103N resistance mutation was detected 6 weeks after Nevirapine administration in 3/15 (20%) women in the HIVNET006 phase I/II trial. This had the same Nevirapine dosing schedule as HIVNET012 (12).

New information has become available based on recent post-marketing surveillance data clarifying risk factors for severe life threatening and fatal hepatotoxicity with nevirapine. Women with CD4 counts > 250 cellsmm3 at initiation of therapy including pregnant women receiving chronic treatment for HIV infection are at considerably higher risk (12-fold) of hepatotoxicity which in some cases has been fatal. The greatest risk of severe and potentially fatal hepatic events occurs in the first 6 weeks of therapy. However, the risk continues after this time and patients should be closely monitored for the first 18 weeks of therapy. For this reason, women with CD4 > 250/mm3 will not be included in Objective 1 of this study.

Hypothesis

Nevirapine resistance developed in women and infants in the HIVNET 006 and 012 cohorts as a consequence of use of an agent with a long t½ as monotherapy in individuals with high viral loads.

Objective 1 To demonstrate that Nevirapine resistance does not develop in HIV infected patients when used as part of triple antiretroviral combination therapy between the initiation of treatment and suppression of HIV RNA to <1000 copies/ml.

Objective 2 To demonstrate that resistance to nevirapine does not develop when patients with suppressed HIV RNA discontinue combination antiretroviral therapy which contains nevirapine. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT00193947
Study type Observational
Source University Health Network, Toronto
Contact
Status Terminated
Phase Phase 4
Start date November 2003
Completion date May 2008

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Terminated NCT00319150 - REPEAT Study - Resistance to ErythroPoietin Effectiveness Algorithm Trial Phase 3
Completed NCT00563875 - Laboratory Aspirin Resistance in Diabetics and Non-Diabetics N/A
Completed NCT00389129 - Danish Aspirin Resistance Trial - Pilot Study N/A
Enrolling by invitation NCT06037564 - B-free Multistage Trial Phase 4
Completed NCT04326868 - Human Soil Transmitted Helminths (STH) Resistance to Benzimidazole in School Aged Children Living in Gabon Phase 4
Completed NCT01039480 - Aspirin and Clopidogrel Resistance Study N/A
Recruiting NCT05310370 - HRD and Resistance to PAPPi in EOC Patients
Active, not recruiting NCT00457236 - Effect of Clopidogrel Loading and Risk of PCI N/A
Completed NCT02792816 - Molecular Surveillance of Artemisinin Resistance Malaria in Myanmar N/A
Completed NCT01386476 - (18F)FCWAY and the Blood-Brain Barrier
Recruiting NCT04990596 - Mechanisms fo Clopidogrel Resistance in Older Adults (CEPAGE)
Recruiting NCT03401957 - The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment N/A
Completed NCT04404582 - Clinical Characteristics for the Critical Ill Patients With Klebsiella Pneumoniae Infection
Completed NCT02401204 - Bacterial Transmission Dynamics Study
Completed NCT03114098 - Pharmacogenetics Anomaly Research in Children and Adolescents With Pharmacological Resistance to Psychotropic Drugs N/A
Recruiting NCT03361267 - Comparison of Bismuth Containing Quadruple Therapy and Based Tailored Therapy for H. Pylori Infection N/A
Completed NCT00302913 - Efficacy of Adjusted Clopidogrel Dose in Patients With Insufficient Platelet Inhibition N/A
Completed NCT04833231 - The Relationship Between Renal Functions and Multi Drug Resistant Organisms
Completed NCT00965042 - Effect of Ceftobiprole on Human Intestinal Microflora Phase 1